Genmab — November 2020

[Sukkeralf]

Skorney noted that the validation provided by these two bispecifics could give a boost to the rest of Regeneron’s portfolio, and “should help support a long-term pipeline thesis.”

[Sukkeralf]

Set i lyset af at der kommer stort fokus på BsAbs i ved Genmabs CMD, så kunne det jo ligeledes give større og større håb for Genmabs måske førende position indenfor dette område

[Sukkeralf]

Analytikere øjner opjustering:

[Sukkeralf]

Analytiker øjner opjustering fra Genmab

Der kan være en opjustering på vej fra medicinalselskabet Genmab, der onsdag fremlægger sine tal for tredje kvartal, vurderer Sydbank på baggrund af tal fra partneren Johnson & Johnson, som allerede for mere end 14 dage siden løftede sløret for et bedre end ventet salg af kræftmidlet Darzalex.

(medwatch.dk)

[E_L]

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/27/469910/Updated-Phase-1-Results-of-Teclistamab-a-B-Cell?searchresult=1

[E_L]

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models https://ashpublications.org/blood/article/136/Supplement 1/19/471645/Preclinical-Anti-Tumor-Activity-of-Hexabody-CD38?searchresult=1

[E_L]

GEN3013 -
Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies https://ashpublications.org/blood/article/134/Supplement_1/4066/424296/Duobody-CD3xCD20-Induces-Potent-Anti-Tumor?searchresult=1

[E_L]

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas https://ashpublications.org/blood/article/134/Supplement_1/758/426903/First-in-Human-Phase-1-2-Trial-to-Assess-the?searchresult=1

[E_L]

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies https://ashpublications.org/blood/article/132/Supplement 1/1664/273265/Duobody-CD3xCD20-Shows-Unique-and-Potent?searchresult=1

[E_L]

Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody Antibody Treatment https://ashpublications.org/blood/article/128/22/5215/100049/Immunoprofiling-of-Normal-Human-Donor-Blood?searchresult=1

[E_L]

forget that last one, it is old offcourse

[E_L]

i just picked 1 Dara abstract, too many to post all

[E_L]

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

[E_L]

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/40/470139/A-Phase-1-First-in-Human-Study-of-Talquetamab-a-G?searchresult=1

[E_L]

very interesting. had Talquetamab as a lotery ticket, early data encouriging though, even though a few grade 3 crs
?

[E_L]

MTD has not been defined and dose escalation continues, with the study nearing a RP2D.

[Bulder]

Yes, but only grade 1-2 with sc dosing. Amd it looks that they have decided for sc, as that is the chosen adm in the combination study.

[Bulder]

301 Moved Permanently

(www.clinicaltrials.gov)

[E_L]

that is a good point. the PhII is also SC https://clinicaltrials.gov/ct2/history/NCT04557098?A=1&B=2&C=merged#StudyPageTop

[E_L]

ORR was a bit higher at IV though, probably still have to jack up the SC dose a bit